Our journey started from the dreaming spires of Oxford. We are a multidisciplinary team with extensive expertise in cancer research, clinical medicine, machine learning and business on a mission to bring hope to cancer patients and their families worldwide
Learn about our team
.webp)
January 9, 2025
Oxford Cancer Analytics (OXcan), the medtech company developing blood tests for early cancer detection using advanced proteomics and AI, today announced it has raised US$11 million in Series A funding from global investors, including in-field institutional investors in disease detection and diagnostics. With the close of this round, Dr. Heinrich Roder, expert in lung cancer proteomics liquid biopsy, was appointed as Senior Vice President of Research and Development at OXcan.
January 10, 2023
Oxford Cancer Analytics is pioneering a new generation of blood based liquid biopsy tests for early cancer detection, and has announced the completion of an additional seed financing round, led by Eka Ventures, with participation from LifeArc, MegaRobo Technologies, Oxford Technology Management, and value-add individual investors.
December 16, 2022
The team from Oxford University Hospitals (OUH) NHS Foundation Trust, the Oxford Radcliffe Biobank and the local spin-out company Oxford Cancer Analytics (OXcan) will recruit 200 participants to identify cancer biomarkers - molecules such as proteins found in blood that are a sign of lung cancer.
.svg)
%20(1).svg)
